1. Home
  2. MIRM vs MHF Comparison

MIRM vs MHF Comparison

Compare MIRM & MHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$79.64

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Logo Western Asset Municipal High Income Fund Inc.

MHF

Western Asset Municipal High Income Fund Inc.

HOLD

Current Price

$6.92

Market Cap

150.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
MHF
Founded
2018
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
150.1M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
MIRM
MHF
Price
$79.64
$6.92
Analyst Decision
Strong Buy
Analyst Count
11
0
Target Price
$92.45
N/A
AVG Volume (30 Days)
790.7K
57.2K
Earning Date
11-04-2025
01-01-0001
Dividend Yield
N/A
4.29%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$471,794,000.00
N/A
Revenue This Year
$53.78
N/A
Revenue Next Year
$19.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
53.66
N/A
52 Week Low
$36.88
$5.92
52 Week High
$79.95
$6.79

Technical Indicators

Market Signals
Indicator
MIRM
MHF
Relative Strength Index (RSI) 69.86 44.95
Support Level $63.23 $6.88
Resistance Level $66.77 $6.98
Average True Range (ATR) 3.33 0.08
MACD 0.90 -0.00
Stochastic Oscillator 98.15 20.60

Price Performance

Historical Comparison
MIRM
MHF

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About MHF Western Asset Municipal High Income Fund Inc.

Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.

Share on Social Networks: